Although the causal role of Human papillomavirus (HPV) Relating to HPV, three prognostic groups were observed. The better clinical outcome was related to genotypes other than HPV16/18/45, while HPV16/18 genotypes belong to an intermediate risk group and the worse prognosis was related to HPV negative and HPV45. HPV independent tumors have been suggested as a different entity compared with virally driven ones. Improvement in knowledge of molecular pathogenesis could impact in CC patients care. In conclusion, worse prognosis was related to HPV negative and HPV45 related tumors. More research is warranted for better understanding molecular basis of virally driven or independent cervical cancer oncogenesis.
INTRODUCTION
Despite diagnosis progress and preventive actions, cervical cancer (CC) is still a public health concern, especially in developing countries. According to data from the International Agency for Research on Cancer (IARC), of the World Health Organization, it is the fourth most frequent cancer worldwide, and the fourth cause of cancer-related death in women (GLOBOCAN 2012) . CC is one of the main examples of health inequity as 85% of cases, as well as 9/10 related death occur in developing countries (Ferlay, 2015) . In Uruguay, it is the third most frequent cancer in women, after breast and colorectal cancer, with an average of 330 new cases per year, which represent an incidence rate of 15.69 and a mortality rate of 5.33 death per 100,000 population (approximately 133 deaths per year) (Barrios, 2014a; Barrios, 2014b) .
The carcinogenic implication of HPV infection in CC development is largely accepted, although progression to CC only occur in a small percentage of women, and most of them clear the infection (Schiffman, 2007) . Understanding the genetic basis of HPV oncogenicity is highly complex, but innovative analytic methods are improving our knowledge about susceptibilities to HPV typespecific infection and cervical progression (Zou, 2016) . Among the accepted HPV oncogenic genotypes (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) , prevalence has shown to be highly variable by geographical region, sexual behavior and age. It is widely accepted that genotypes 16 and 18 are the main contributors to HPV-related cervical carcinogenesis. These genotypes are also responsible for a subset of tumors in other locations such as oropharyngeal, and anogenital cancers in both sexes, and seem to play a role in other digestive cancers like esophagus and colorectal cancer although evidences are still inconclusive for these localizations (Zumsteg, 2016; Bucchi. 2016) . Vaccination represents a good strategy to reduce the burden of HPV-related cancers. Two first approaches (bivalent and tetravalent) include main oncogenic genotypes (HPV16 and HPV18), covering upto 70% of HPV-related CC, and a second generation vaccine (nonavalent) covers upto 90%. Vaccine implementation programs led to controversial discussions and a conclusion on its actual efficacy require a 20 years follow-up period. After the first ten years it can be concluded that vaccines are safety and efficient, but the superiority of vaccination in preventing CC compared to HPV screening is not proven yet (Angioli, 2016) .
Numerous methods are available for HPV detection and genotyping, although not all of them have the same performance, which could explain the variation in reported prevalence in the literature. Although the PCR-based methods seem to be one of the most sensitive, several cases of CC remain HPV negative after re-analysis, and it has been suggested that this subset of tumors could represent a more aggressive group (Rodríguez-Carunchio, 2015) . Similar results were found for head and neck (H&N) tumors (Liu, 2017) and anal cancer (Mai, 2015) . For invasive CC, the main prognostic factors are stage at diagnosis, tumor size, parametrial spread, regional lymph node status, perivascular invasion and deep stromal invasion (Pecorelli, 2009) . Although etiology of CC is related to HPV infection, the prognostic role of different genotypes, if any, is not clear. Several authors did not find any correlation between HPV genotypes and survival (Tong, 2007; Cuschieri, 2014; Lau, 2015) , while others found intermediate risk HPV correlating with better outcome than high risk genotypes (de Cremoux, 2009; Huang, 2004) . Indeed, controversial results involve also the two most frequent high risk genotypes. While some authors found HPV16 as an independent prognostic factor for overall survival (Pilch, 2001) , other reports state that HPV16 is more frequent in patients surviving more than 5 years (Dahlgren, 2006) . Otherwise, greater consensus seems to hold HPV18 as a worse prognosis factor, especially for low stages (Schwartz, 2001; Lai, 2007; Yang, 2014 We previously reported the only study of prevalence and distribution of HPV genotypes in invasive CC carried out in Uruguayan women, which showed HPV16, 18 and 45 as main prevalent genotypes (Berois, 2013) . In view of contradictory data concerning the influence of HPV genotypes on the clinical outcome of CC patients, at the present work our aim was to review clinical records of same patients in order to evaluate the prognosis significance of HPV-status and its relationship with clinical-pathological variables.
MATERIALS AND METHODS

Patients and clinical-pathological data
The present study is an update of our previous report about the prevalence and genotype distribution of HPV infection in 176 patients with invasive CC treated at the Centro Hospitalario Pereira Rossell in Montevideo, Uruguay (Berois, 2013) . Medical records were reviewed in order to collect information and patients were selected based on the availability of data about their stage at diagnosis, histopathological features, treatments and outcome. A total of 121 patients met these inclusion criteria. The study was reviewed and approved by the ethical review boards of the School of Medicine (Universidad de la República) and the Ministry of Public Health of Uruguay.
Treatments
Patients were treated according to accepted protocols and following the FIGO staging system (FIGO Committee on Gynecologic Oncology, 2014). Treatment plans were decided in Gynecologic Tumor Board meetings formed by gynecologists, medical and radiation oncologists as well as pathologists. To sum up, surgery (cone, simple or radical trachelectomy, radical hysterectomy, and pelvic lymphadenectomy), radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) was chosen depending on different factors, such as the FIGO stage, the prognostic factors and the reproductive desires of the patient. Although surgery and RT show similar results in early stages, surgical is the treatment of choice. Patients with locally advanced disease received RT (combination of external beam RT and intracavitary brachytherapy) or CCRT with radical purpose. The treatment standardized according to the lesion extension based on clinical examination and computed tomography consisted of 48.8 Gy delivered to the whole pelvis, followed by a parametrial reinforcement of 14 Gy. Brachytherapy is individually adjusted according to the tumor size, and the dosage as well, depending on the tolerance of the tissues. As far as CCRT is concerned, the regimens used were based on cisplatin at doses of 40 mg / m2.
Specimen preparation and HPV genotyping
HPV genotyping was performed by Polymerase chain reaction (PCR), as previously described (Berois, 2013) . In short, formalin-fixed paraffinembedded tissue blocks having more than 10% of tumor cells were used for DNA extraction by a commercial kit (QIA ampDNA mini kit, Qiagen, Valencia, CA). PCR amplification was performed using GAPDH gene sequence primers, in order to evaluate DNA quality, and HPV detection was assessed by generic primers GP5+/6+ and specific primers for HPV16, 18, 33 and 45 genotypes. Positive GP5+/GP6+ samples -but negative for all HPV-specific types screened-were further analyzed by sequencing and aligned with reference sequences for genotype identification.
Statistical Methods
Contingency tables involving qualitative variables were tested using Chi square test or Fisher exact test, when needed. Overall survival distribution time was estimated using the Kaplan-Meier method. Survival curves were compared using logrank test. Cox Proportional Hazard Model was used for multivariate analysis, but sample size limitations were critic in order to reach statistical significance. significant. Statistical analysis was performed using STATA version 14.2 software.
RESULTS
The population included in this analysis was 121 patients. Although it is fewer than the population of our first report (n = 176), the characteristics of the patients are similar. (Figure 1 ). Table III shows survival analysis of patients with CC who underwent radical hysterectomy. Twenty out of 74 patients had lymph node metastasis and survival rate was 55% for node-positive patients and 88.9% for node-negative ones (p = 0.001) (Table III) . Figure 3: Kaplan-Meier curves for overall survival stratified by HPV status, all stages included.
DISCUSSION
The most important prognostic variables of CC are FIGO stage, lymph node status and clinicalpathological features of primary tumor such as size, depth of stromal invasion, parametrial or vaginal involvement, lymph-vascular space involvement and histological type (Berek 2010) . Although histological types have been suggested as independent prognostic factors (Mabuchi, 2012; , no significant differences in OS were found in our population. In agreement with Bradbury et al. we found significant correlation of OS with lymph node metastasis but not extrauterine invasion (Table III) (Bradbury, 2015) , although other authors reported significant correlation of parametrial involvement with disease-free and overall survival (Jiamset, 2016 (Mao, 2016) . Current literature suggests that patients with low-risk early-stage CC may be candidates for more conservative approaches, preserving reproductive function (Baiocchi, 2017; Willows, 2016) . In contrast, CCRT is the standard of care in locally advanced stages of CC, which exceed the limit of the cervix towards parametria, annexes or pelvic organs (FIGO stages IB2, IIA2-IV) (Meng, 2016) . Neoadjuvant chemotherapy followed by radical hysterectomy is a promising therapeutic option for stage IB2-IIB disease (Gadducci, 2017) . Although in our OS analysis (Table II ) it seems that surgery treatment is a better option compared with RT/CCR, certainly this is because most non operated patients belong to advanced stages. Only 2 patients with early stage were treated by RT without surgery, and both are alive (data not shown).
Recently, in the era of precision medicine, increasing evidence in databases suggest the potential usefulness of deregulated genes as biomarkers able to predict both, response to treatment and survival, as well as molecular targets in CC patients (Niu, 2017) . Among several examples, MVP (major vault protein), IGF-1R (insulin-like growth factor 1 receptor), and BCL2 (B cell lymphoma 2) expression in tumor tissues have been suggested as useful biomarkers for an optimal planning of therapeutic strategy (Valenciano, 2014) . Furthermore Foxp3 (forkhead/winged helix transcription factor p3) and TLR4 (toll-like receptor 4) could play a role in promoting the immune escape of CC suggesting a potential rational for new immunotherapeutic strategies (Zhang, 2017) . However, lacking of phase III trial conclusions, no tissue biological variables can still be used nowadays in the clinical practice to better define the prognosis or to tailor treatment strategies of patients with CC . The etiopathogenic association between HPV infection and CC is well established (Bosch, 2002) . However, although increasing evidence supports the link between HPV status and disease prognosis, a large number of controversial reports do not allow conclusive remarks. Some authors suggest that HPV genotype has significant value to predict OS and disease free survival (Lai, 2007; Wang, 2010) , while other reports state otherwise (Lau, 2015; Tong, 2007 (HPV 31, 33, 35, 39, 52, 53, 58, 59, 73) although OS did not reach statistical significance (de Cremoux, 2009) . In Asian population, in which HPV58 and related genotypes (52 and 33) are more prevalent, similar results were found. Ferdousi et al, in agreement with Lai et al, reported better outcome related to HPV58 (Ferdousi, 2010; Lai, 2007) , while in the series of Huang et al, HPV31 was a significant predictor of good prognosis, independent of clinical stage (Huang, 2004) .
Concerning most prevalent genotypes HPV16/18, several studies have shown that patients with HPV18-containing tumors were at increased risk of death and disease recurrence, especially in early stage disease (Schwartz, 2001; Kang, 2011; Yang, 2014) , while for Pilch et al. HPV16 genotype had an independent negative impact on overall survival in 204 patients with CC (Pilch, 2001 (Riou, 1990; Lai, 2013; Rodríguez-Carunchio, 2015; Okuma, 2016 (Cuschieri, 2014) . In the same way, two studies conducted in Chinese women, where most prevalent HPV genotypes are HPV16, 18, 52 and 58, did not find significant association between OS and infection with a particular HPV type, except for a slightly trend to better survival in HPV58 single-infected patients found by Shah et al. (Lau, 2015; Shah, 2009 (Liu, 2017) . It has been suggested that an underlying mechanism dependent on these two proteins could explain higher sensitivity to RT/CCRT in H&N-HPV positive tumors (Perri, 2015) , as well as in genital tumors (Wakeham, 2017; Wang, 2010) . Moreover, immune response to HPV infection increases tumor-infiltrating lymphocytes (TILs), which have been related to favorable prognosis in many solid tumors. In H&N tumors a distinct B-cell signature between virally driven tumors compared with virus independent ones have been demonstrated (Wood, 2016) , which let to argue about biological variation in adaptive immune responses explaining different clinical outcome. In CC a large polyclonal repertoire of T cells HPVspecific have been demonstrated within the total population of TILs as well as in tumor-draining lymph nodes (de Vos van Steenwijk, 2010) . In a therapeutic approach, objective regression of metastasis in CC patients by HPV-TILs enables to discuss about their immunological role, which could explain more aggressive behavior in HPV-negative tumors and encourages research for immunotherapy strategies in CC (Stevanović, 2015) .
In conclusion, saving limitations due to the retrospective condition of this study, in which treatment protocols could evolve over time, we observed a significant correlation of FIGO staging and lymph node metastasis with overall survival, in 
